Medicare wants to save enrollees money on prescriptions and is asking for input on how to accomplish that goal. It issued a request Thursday for public comment on more effective ways to pass on Part D savings achieved through manufacturer rebates and pharmacy price concessions. CMS acknowledged that when these discounts are not reflected at the point of sale, Medicare beneficiaries often pay lower premiums but typically are responsible for a bigger chunk of a drug's actual cost. While it could take until 2020 to fully revamp the process, some proposed components—such as treating cheaper biosimilars the same as generics when calculating out-of-pocket costs and permitting mid-year changes in drug formularies to accommodate for new generics—could be adopted sooner. Medicare is accepting feedback until January 16, 2018.